Goldman Sachs Annual Global Goldman Sachs Annual Global Healthcare ConferenceHealthcare Conference

Geno GermanoPresident – U.S. and General Manager, Wyeth Pharmaceuticals

June 12, 2007June 12, 2007

Forward-Looking Statement

The statements in this presentation that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, the impact of competitive or generic products, product liability and other types of lawsuits, the impact of legislative and regulatory compliance and obtaining approvals, and patent, and other risks and uncertainties, including those detailed from time to time in Wyeth’s periodic reports, including quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Quarterly results, in particular, can vary due to issues which include, but are not limited to, changes in exchange rates, the timing of actions taken by the Company to ensure long-term improvements to our manufacturing processes, the timing of regulatory approval of new products and/or facilities and the timing of promotional programs. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Driving Wyeth’s Growth

n Reliable Safety and Efficacy Profile4 Over 470,000 Patients Treated Worldwide

4 Over One Million Patient Years Market Experience

n ~360,000 Incremental Biologic Patients in Top 6 EU Countries

n ~60,000 Incremental Biologic Patients in Japan4 Japanese Post Marketing Surveillance Program Lifted 2Q07

n Significant Growth Opportunities Exist4 Biologics Market Penetration:

- RA: U.S. = ~33%; EU = ~20%

- Psoriasis: U.S. = ~8%; EU = <1%

$3 Billion Enbrel Sales in 2010(Outside North America)

Driving Wyeth’s Growth

n Launched in 79 Countries; Additional 9 Launches by 2008

Birth CohortsCurrent and Emerging Market Opportunities

~ 58 MillionPrivate Markets(e.g. China, India, Pakistan, Russia)

~ 8 MillionPrivate to Potential National Immunization Programs(e.g. Brazil, Czech Republic, Turkey)

~ 3 MillionPotential National Immunization Programs(e.g. Austria, Denmark, Finland, Ireland, Japan)

~ 10 MillionCurrent National Immunization Programs(16 Programs to Date)

$3 Billion Prevnar Sales in 2010(Infant Vaccination)

®®

Recent FDA Approvals

n Lybrel™ - Approved May 20074First Low Dose Combination Oral Contraceptive Offering Women the

Opportunity to Be Period-Free Over Time

4U.S. Launch Expected in July 2007

n Torisel™ - Approved May 20074Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced

Kidney Cancer

4Proven to Extend Overall Survival for People with Advanced Renal Cell Carcinoma

4U.S. Launch Expected in July 2007

January 2008Opioid Induced Constipation

Methylnaltrexone (Sub Q)

Year End 2007Osteo PreventionViviant™

August 2007SchizophreniaBifeprunox

Late July 2007VasomotorPristiq™

1Q 2008

Expected FDA Action

DepressionPristiq™

IndicationProject

Future Wyeth Growth DriversNew Pharmaceutical Products Pending FDA Approval

Pristiq™: A Single Product With Multiple Uses in a Large Population

n First Line Treatment ofMajor Depressive Disorder Associated With Menopause

n Excellent Results Achieved With Low Dose Studies4 Demonstrated Efficacy at 50 mg

Dose4 Replicated Efficacy at 100 mg Dose

4 Reduction in Adverse Event Related Discontinuation Rates

4 Substantial Improvement in Nausea Rates and Overall Tolerability

n 50 mg Dose is Optimal Dose for Depression

n First FDA-ApprovedNon-Hormonal Treatment of Moderate-to-Severe VMS

n Submitted Results From Study of 100 mg and 150 mg Doses With Three-day 50 mg Starting Dose4 Markedly Reduced Incidence of

Nausea and Adverse Event Related Discontinuations

4 Confirmed Efficacy of the 100 mg and 150 mg Doses

Depression Vasomotor Symptoms

PanicPanic

GADGAD

VasomotorSymptoms

VasomotorSymptoms MDDMDD FibromyalgiaFibromyalgia

23 Million Women

4 Million Women

12 MillionWomen

~2 to 3 Million Patients

>35 Million WomenU.S. Prevalence1)

Pristiq™ Market Possibilities(U.S.)

2006

1) 2006 Syndicated Depression Omnibus shows VMS and depression overlap of ~3M women, 2005 Depression Consumer; Landscape Study shows fibromyalgia and depression overlap of ~1M women

SADSAD

+ +

Late 2007Menopausal Symptoms/

OsteoporosisAprela™

Submitted 2Q07HemophiliaReFacto® AF

Mid 2007CAP/HAPTygacil®

Early 2008Post Operative Ileus

Methylnaltrexone (I.V.)

Proposed FilingIndicationProject

Future Wyeth Growth DriversNear Term FDA Submissions

Aprela™: Optimal Targeted Response ofTissue Selective Estrogens Complex (TSEC)

n Product Profile4Relieves Vasomotor Symptoms

4Prevents Osteoporosis

4Improves Vulvovaginal Atrophy (VVA)

4Excellent Amenorrhea

4Less Breast Tenderness

4Provides Endometrial Protection Without Progestin

n NDA Filing: Late 2007

The Most Comprehensive Medicinefor Menopause

The Most Comprehensive Medicinefor Menopause

Global Revenue = $2 Billion

Premarin Family in 2001n ~13 Million Women Worldwide

n Less Than $1.00 Per Day

Aprela™ Market Possibilities

Global Revenueð$2 Billion +

Aprela’s Possibilitiesn Capture a % of Lost Patients

n Modern Day Pricing

Global Revenue = $1 Billion

Premarin Family Todayn ~3 Million Women Worldwide

n About $1.00 Per Day

Positioning Wyeth To Be A Stronger Company

n Build Breadth and Diversity Into Every Aspect of the Company So Wyeth Will Never Be Dependent on One Product or Any One Research Program

n Continue to Improve Profitability by Enhancing Productivity

n Achieve Solid Top Line Growth, Effectively Manage Costs, and Grow the Bottom Line at a Meaningfully Faster Rate Than the Growth in Revenues

Position Wyeth to Be a Stronger Company at the End of the Decade Then We Are Today and Enter the Next Decade With

Great Momentum